| Document |
Document Title |
|
WO/2022/208382A1 |
The present invention provides a compound of chemical formula 1, a compound of chemical formula 3, compound [212], compound [224], or compound [228], a pharmaceutically acceptable salt thereof, a stereoisomer thereof, a hydrate thereof, ...
|
|
WO/2022/206350A1 |
Provided herein are inhibitors of methionine aminopeptidase 2 (MetAP-2) and pharmaceutical compositions thereof, and their use and methods of treatment, reduction or prevention of certain diseases or conditions associated with MetAP-2 (e...
|
|
WO/2022/212815A1 |
Described are 6-aryl quinazolin-4(3H)-ones as negative allosteric modulators of metabotropic glutamate receptor 2 (mGlu2), pharmaceutical compositions including the compounds, and methods of using the compounds and compositions for treat...
|
|
WO/2022/207462A1 |
Compounds of formula (I) wherein the substituents are as defined in claim 1, and the agrochemically acceptable salts, stereoisomers, enantiomers, tautomers and N-oxides of those compounds, can be used as insecticides.
|
|
WO/2022/206742A1 |
The present invention belongs to the technical field of medicine synthesis, and in particular relates to a method for synthesizing a thiohydantoin derivative by means of a one-step method. By means of taking three components, i.e., an am...
|
|
WO/2022/206010A1 |
Disclosed in the present invention is a simple preparation method for isoxazolines, comprising: using aldehyde, p-toluenesulfonyl hydrazide, olefin, and tert-butyl nitrite as a substrate, using copper chloride as a catalyst, using tetram...
|
|
WO/2022/205586A1 |
A preparation method for a pyrrole-2-sulfonamide compound or a pharmaceutically acceptable salt thereof, and an application thereof in preparing an anti-tumor drug, the pyrrole-2-sulfonamide compound having a structure represented by for...
|
|
WO/2022/208262A1 |
The invention relates to compounds of Formula I and pharmaceutically acceptable salts thereof wherein R1, R2, R3, p, q, q' and Ring A are as defined herein, pharmaceutical compositions comprising the compounds, methods of treating corona...
|
|
WO/2022/200162A1 |
The present invention relates to a compound of the general formula (I). The compounds of formula I are useful for treatment of a cardiac disease, disorder or condition in a mammal.
|
|
WO/2022/203246A1 |
The present specification relates to a compound represented by chemical formula 1 and an organic light-emitting device comprising same.
|
|
WO/2022/202537A1 |
A fluorinated pyrimidine compound represented by general formula (1a) or (1b). (In general formulae (1a) and (1b), R1 represents a hydrocarbon group having 1 to 12 carbon atoms; R2 represents a halogen atom, a hydrocarbon group having 1 ...
|
|
WO/2022/203399A1 |
The present invention relates to an antagonist of an adenosine A2A receptor, a pharmaceutical composition containing same for preventing or treating adenosine A2A receptor-related disease (for example cancer), and a method for treating a...
|
|
WO/2022/204683A1 |
Disclosed herein are quinazolinyl compounds, compositions, and methods of use thereof. The compounds may be used in the treatment of kinase-related disorders (including cancer, autoimmune disease, and Duchenne muscular dystrophy).
|
|
WO/2022/202864A1 |
The present invention relates to: a compound, or a pharmacologically acceptable salt thereof, that has GLP-1 receptor agonist activity and that is useful as an agent for treating or preventing diseases involving the GLP-1 receptors; and ...
|
|
WO/2022/204299A1 |
Compounds having activity as inhibitors of LRRK2 kinase are provided. The compounds have Structure (I): or a pharmaceutically acceptable salt, stereoisomer or prodrug thereof, wherein A, B, R1a, R1b, R2, and L are as defined herein. Meth...
|
|
WO/2022/199611A1 |
Provided is a heterocycle substituted ketone derivative, the structure of which is as shown in formula (I). Further provided are a pharmaceutically acceptable salt of the derivative, a stereoisomer thereof, a pharmaceutical composition a...
|
|
WO/2022/199815A1 |
The present invention relates to compounds of general formula (I) inhibiting lysophosphatidic acid receptor 2 (LPA2), particularly the invention relates to compounds that are 8-cyclo-substituted quinazoline derivatives, methods of prepar...
|
|
WO/2022/204227A1 |
The present disclosure relates to compounds that act as inhibitors of NLRP3 inflammasomes; pharmaceutical compositions comprising the compounds; and methods of treating disorders associated with inflammation and inflammaging, including h...
|
|
WO/2022/199367A1 |
The present invention relates to the technical field of pharmaceutical chemistry, and provides a dithiocarbamate compound and a preparation method therefor, a pharmaceutical composition, and applications. The dithiocarbamate compound pro...
|
|
WO/2022/200208A1 |
Substituted pyrrolidin-2-ones, salts thereof and their use as herbicidally active substances The present invention relates to substituted pyrrolidin-2-ones of the general formula (I) or salts thereof, (I) where the radicals in the genera...
|
|
WO/2022/199654A1 |
The present disclose includes, among other things, compounds that treat or lessen the severity of cancer, pharmaceutical compositions and methods of making and using the same.
|
|
WO/2022/199662A1 |
Provided are a compound represented by general formula (I), or a tautomer, mesomer, racemate, enantiomer, diastereomer or mixture thereof, a deuterium isotopic derivative, pharmaceutically acceptable hydrate, solvate, salt, or eutectic t...
|
|
WO/2022/193499A1 |
Provided herein are novel compounds (e.g., Formula I or II), pharmaceutical compositions, and methods of using related to Tyrosine kinase 2 (TYK2). The compounds herein are typically TYK2 inhibitors, which can be used for treating a vari...
|
|
WO/2022/198112A1 |
Bifunctional compounds, of formula PTM-L-CLM, where the CLM is of formulae al-a4, the PTM f formula PTM-IA and L is a ligand. These compounds act on several diseases via agonism on LRRK2 and cereblon E3 ubiquitin ligase.
|
|
WO/2022/198003A1 |
Described are 6-aryl isoindolin-1-ones as negative allosteric modulators of metabotropic glutamate receptor 2 (mGlu2), pharmaceutical compositions including the compounds, and methods of using the compounds and compositions for treating ...
|
|
WO/2022/194191A1 |
Provided are heterocyclics as inhibitors of KRAS G12D, in particular a compound of Formula I or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising said compound that are useful for treatment of KRAS G...
|
|
WO/2022/197069A1 |
The present invention relates to a novel compound and a pharmaceutical composition containing same for treatment or prevention of transglutaminase-2-related diseases. Being capable of inhibiting transglutaminase-2 activity with significa...
|
|
WO/2022/195355A1 |
The present disclosure relates to compounds of formula (I) and pharmaceutical compositions and their use in reducing Widely Interspaced Zinc Finger Motifs (WIZ) expression levels, or inducing fetal hemoglobin (HbF) expression, and in the...
|
|
WO/2022/194259A1 |
It provides compounds of Formula I, compositions comprising the same, and methods of using the same, including use in treating various diseases and conditions, including those mediated by receptor-interacting protein 1 (RIP1) signaling.
|
|
WO/2022/197884A1 |
The present disclosure encompasses solid state forms of Zandelisib and HCI or HBr salts thereof, processes for preparation thereof, and pharmaceutical compositions thereof.
|
|
WO/2022/198062A2 |
A compound of Formula I includes a stereoisomer thereof and/or a salt thereof; wherein R1 is a substituted alkane group, a heterocylic group, or a pyridine group; X is hydrogen, a halogen, an amino acid residue, a substituted amino acid ...
|
|
WO/2022/194237A1 |
Provided are a quinoline derivative represented by general formula (I) and an application thereof in the preparation of an autoimmune drug.
|
|
WO/2022/197658A1 |
Compounds that induce expression of ATP-binding cassette transporter Al (ABCA1 ) without lipogenesis are provided, as are methods of using the same to treat or prevent type 2 diabetes or dementia.
|
|
WO/2022/189810A1 |
This invention relates to compounds that can be used to treat viral infections. The compounds are papain-like protease (PLpro) inhibitors.
|
|
WO/2022/192648A1 |
An active material is orally administered to a mammal substantially daily, which eventually increases the mammal's blood concentration of the active material to an amount effective to control a flea and/or tick infestation of the mammal....
|
|
WO/2022/191292A1 |
The present invention provides an industrially preferred method for producing a sulfone derivative that is useful as an herbicide.　This method is for producing a compound of formula (2). In the method, a compound of formula (1) is reac...
|
|
WO/2022/192745A1 |
Disclosed are compounds of Formula IIA, IIA-1, IIB, IIB-1, IIC and IIC-1: and pharmaceutical compositions and methods of use thereof These compounds inhibit Protein Arginine M-Methyl Transferase 5 (PRMT5) activity and are useful in metho...
|
|
WO/2022/192533A1 |
Disclosed herein are kinase inhibitory compounds, such as a receptor¬ interacting protein-1 (RIP1) kinase inhibitor compounds of formula (I), as well as pharmaceutical compositions and combinations comprising such inhibitory compounds. ...
|
|
WO/2022/188735A1 |
Provided are heterocyclics as inhibitors of HPK1, in particular a compound of Formula I or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising said compound that is useful for treatment of HPK1 mediate...
|
|
WO/2022/192431A1 |
The present disclosure provides a compound represented by structural formula (1-0): or a pharmaceutically acceptable salt thereof useful for treating a cancer.
|
|
WO/2022/192430A1 |
The present disclosure provides GLP-1R agonists of formula (I), and compositions, methods, and kits thereof. Such compounds are generally useful for treating a GLP-1R mediated disease or condition in a human.
|
|
WO/2022/187633A1 |
Compositions and methods for control and/or modification of endogenous protein acetylation are described. The compositions are directed to heterobifunctional molecules having protein and enzyme binding moieties linked together by an orga...
|
|
WO/2022/186133A1 |
In agricultural and horticultural crop production, there is still a great amount of damage due to pests and the like. Thus, the present invention addresses the problem of providing a novel agricultural/horticultural pesticide from the vi...
|
|
WO/2022/187200A1 |
Provided herein are compounds and methods for the treatment of cancer. The methods include administering to a subject in need a therapeutically effective amount of a of RNR inhibitor disclosed herein.
|
|
WO/2022/187282A1 |
The present disclosure provides compounds useful as amino acid transporter inhibitors. Amino acid transporter inhibitors are useful to treat a variety of diseases, disorders, or conditions including cancer.
|
|
WO/2022/185241A1 |
The present invention provides a process of synthesizing 1-(((Z)-(1-(2-aminothiazol-4-yl)-2-oxo-2-(((3S,4R)-2-oxo-4-(
(2-oxooxazolidin-3-yl)methyl)-1-sulfoazetidin-3-yl)amino)eth
ylidene)amino)oxy)cyclopropanecarboxylic acid, including a...
|
|
WO/2022/185055A1 |
Compounds of the formula (I) and pharmaceutically acceptable salts thereof: (I) wherein the substituents are defined in the specification. The compounds are hyperpolarisation activated cyclic-nucleotide modulated ion channel 2 (HCN2) inh...
|
|
WO/2022/184849A1 |
Compounds of formula (I)
|
|
WO/2022/185057A1 |
Compounds of the formula (I) and pharmaceutically acceptable salts thereof: wherein the substituents are defined in the specification. The compounds are hyperpolarisation activated cyclic-nucleotide modulated ion channel 2 (HCN2) inhibit...
|
|
WO/2022/182547A1 |
This disclosure is directed to agonists of the apelin receptor (APJ) and uses of such agonists.
|
